Le LÚzard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Personnel

Inflammatix Appoints Dr. Kian Beyzavi as New Board Member


Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company's board of directors.

Dr. Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis and delivery of care. Since starting her career at McKinsey & Company, she has over 25 years of experience as a venture investor, entrepreneur, consultant, and general manager at Rho Ventures, Cubit Software, Medtronic, Abbott Diabetes Care and Novartis Diagnostics. Through her work with multiple stakeholders, Kian has developed a systems-level view of the complex healthcare ecosystem. For the past 10 years she has led a specialized consulting firm advising Fortune 500 companies, startups and others in the areas of strategy, product development, business model innovation, commercialization, and monetization of novel opportunities across life sciences. She is currently a venture partner at Cota Capital, a multistage investment firm.

"We are delighted to welcome Kian to the board. She brings a wealth of vision and deep commercialization experience across diagnostics to her new role with the company. We are drawn to her commitment to leverage technology in improving healthcare and are eager to tap into her insights as we utilize AI and genomics in our mission to improve the diagnosis of infection," said Inflammatix CEO and Co-Founder Timothy Sweeney, MD, PhD.

Dr. Beyzavi added, "I'm thrilled to join the board. Inflammatix is poised to address important unmet needs in the diagnosis of acute illness, which will result in improved treatment decisions and outcomes. I look forward to working with this innovative team as they bring their breakthrough technologies to market."

About Inflammatix

Inflammatix is a molecular diagnostics company that is reimagining diagnostics by reading the patient's immune system to deliver rapid results that improve patient care and reduce major public health burdens. The company's initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Future tests will be developed to run on the company's sample-to-answer isothermal instrument platform in under 30 minutes, enabling the power of precision medicine at the point of care. The Burlingame, CA-based company is funded by leading medical technology investors including Khosla Ventures, Northpond Ventures, D1 Capital Partners, Think.Health Ventures, and others. For more information, please visit www.inflammatix.com and follow the company on Twitter (@Inflammatix_Inc).


These press releases may also interest you

at 20:01
Yosi Health, a provider of digital patient scheduling, registration, payment, and communication cloud-based software solutions, announced today they have added Hants Williams, PhD, RN, a professor at the State University of New York (SUNY) at Stony...

at 20:00
RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial in China for Telitacicept in the treatment of primary Sj÷gren's syndromeá("pSS"). A total of 42...

at 19:30
Demonstrating innovation leadership on a global level, ImmVira announced that, its custom-designed new-generation oncolytic herpes simplex virus ("oHSV") vector enabling CAR-T treatment for solid tumors has started pilot-scale manufacturing and...

at 19:01
Many of us will consider the pre-pandemic world as a harried and often cruel place, littered withástories ofáperennial burn-out and a constant fight for improved 'wellbeing'. But new research from AXA's annual Mind Health Study reveals that although...

at 18:35
The Japan Prize Foundation announced the winners of the 2022 Japan prize today. Prof. Katalin Karikˇ (Hungary/USA) and Prof. Drew Weissman (USA) are co-winners of the Japan Prize in the fields of Materials and Production, and Prof. Christopher Field...

at 18:08
The first molecular electronics chip has been developed, realizing a 50-year-old goal of integrating single molecules into circuits to achieve the ultimate scaling limits of Moore's Law. Developed by Roswell Biotechnologies and a multi-disciplinary...



News published on 30 november 2021 at 07:35 and distributed by: